Cantargia To host R&D Day on New Clinical Results of Nadunolimab in Pancreatic Cancer
Complete the form below to unlock access to ALL audio articles.
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) has announced it will host an R&D Day focusing on new clinical results and biomarker data for its lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), in pancreatic cancer (PDAC) patients, following presentation of these results at the AACR Annual Meeting 2023 (AACR 2023). The R&D Day will be hosted by Cantargia management and Prof. Eric Van Cutsem, principal investigator in the CANFOUR trial.
Cantargia recently announced new results from the phase I/IIa clinical trial CANFOUR, evaluating nadunolimab in combination with chemotherapy for treatment of PDAC, to be presented at AACR 2023 on April 17, 2023. A key finding is that patients with high tumor levels of IL1RAP, the target of nadunolimab, benefit most from the treatment.
During the R&D Day, Prof. Van Cutsem, Division Head of Digestive Oncology at University of Leuven and University Hospitals Gasthuisberg in Leuven, Belgium, and renowned expert in PDAC, will discuss the current treatment landscape in PDAC and the relevance of the new nadunolimab data. He will be joined by Dr. Dominique Tersago and Dr. David Liberg from Cantargia’s management team.
Event details and registration information
· Date and time: April 24, 2023 2:00-3:30 PM CET (8:00-9:30 AM EST).
· Venue: Redeye, Mäster Samuelsgatan 42, 10 tr, Stockholm
The event will be conducted in English and a simultaneous live webcast will be available for those unable to attend in person at the following link. The webcast will also be accessible on-demand, shortly after the event, at Cantargia’s website www.cantargia.com. A live question and answer session will follow the formal presentations. Participation in the event on-site requires registration at the following link.
Program
- Welcome and introduction to Cantargia – Göran Forsberg, CEO
- Nadunolimab mechanism of action – David Liberg, VP Research
- Clinical results including new biomarker data of nadunolimab – Dominique Tersago, CMO
- Pancreatic cancer and relevance of nadunolimab results – Prof. Eric Van Cutsem
- Cantargia's ongoing clinical trials – Dominique Tersago
- Upcoming milestones and concluding remarks – Göran Forsberg
